BMTI, lol...everybody rates it a buy for approval tomorrow, yet iy keeps tanking...
Canaccord Genuity reiterates a 'Buy' on BioMimetic Therapeutics (NASDAQ:
BMTI), PT $18. Canaccord analyst says, "We maintain our rating following the
FDAb s release of the Augment Bone Graft panel briefing documents, which
overall provide a negative tone and have led to a massive sell-off in the
name. While we believe there are legitimate concerns regarding the FDA
questions and issues, we believe the agreed-upon protocol debate and issues
will not necessarily prevent a majority vote for approvable by the clinicians
on the panel." "We note that 9 of 18 voting members are orthopedic surgeons,
and we believe the surgeons will accept the mITT endpoint and therefore be
predisposed in favor of approval." For more ratings news on BioMimetic
Therapeutics click here and for the rating history of BioMimetic Therapeutics
click here. Shares of BioMimetic Therapeutics closed at $8.66 yesterday, with
a 52 week range of $7.96-$14.80.
